Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from AOTI, Inc. ( (GB:AOTI) ) is now available.
AOTI, Inc. has received a positive recommendation from Germany’s Federal Joint Committee (G-BA) for its TWO2® therapy, marking a significant milestone as Germany becomes the first country to grant full national reimbursement coverage. This decision is expected to enhance AOTI’s market penetration across Europe and beyond, aligning with the company’s 2025 business goals. The G-BA’s commitment to formulating reimbursement guidelines for the treatment of Diabetic Foot Ulcers (DFUs) under the German statutory health insurance system could take nine months, providing a framework for collaboration with private healthcare providers in the interim.
More about AOTI, Inc.
AOTI, Inc., founded in 2006 and based in Oceanside, California, and Galway, Ireland, is a medical technology company that provides innovative solutions for severe and chronic wounds. Its primary product, the patented non-invasive Topical Wound Oxygen (TWO2®) therapy, significantly reduces the recurrence of Diabetic Foot Ulcers (DFUs) and associated hospitalizations and amputations. The therapy is approved in multiple countries, including the US, Europe, and China.
Average Trading Volume: 40,393
Technical Sentiment Signal: Strong Sell
Current Market Cap: £95.72M
Find detailed analytics on AOTI stock on TipRanks’ Stock Analysis page.